Synopsis：Moxifloxacin hydrochloride is a fluoroquinolone antibiotic developed by Bayer medicine of Germany. Its mechanism of action and antibacterial spectrum in vitro are similar to other fluoroquinolones, but its antibacterial activity against Gram-positive bacteria and anaerobic bacteria is similar to that of travafloxacin, which is superior to some old varieties. Compared with other fluoroquinolones, there were few or slow resistant Gram-positive bacteria. Cross resistant bacteria with other fluoroquinolones were found in Gram-negative bacteria and Enterococcus. Moxifloxacin hydrochloride can be used in the treatment of social acquired pneumonia, acute attack of chronic bronchitis and acute sinusitis caused by Staphylococcus aureus, influenza bacillus, pneumococcus, Moraxella mucositis, and pneumonia.
Structural formula:
Properties
Summary
Moxifloxacin hydrochloride is a fluoroquinolone antibiotic developed by Bayer medicine of Germany. Its mechanism of action and antibacterial spectrum in vitro are similar to other fluoroquinolones, but its antibacterial activity against Gram-positive bacteria and anaerobic bacteria is similar to that of travafloxacin, which is superior to some old varieties. Compared with other fluoroquinolones, there were few or slow resistant Gram-positive bacteria. Cross resistant bacteria with other fluoroquinolones were found in Gram-negative bacteria and Enterococcus. Moxifloxacin hydrochloride can be used in the treatment of social acquired pneumonia, acute attack of chronic bronchitis and acute sinusitis caused by Staphylococcus aureus, influenza bacillus, pneumococcus, Moraxella mucositis, and pneumonia.
Manufacturing
